Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight
The dynamics of the germ cell tumors market are anticipated to change in the coming years owing to the approval of specialized therapies for GCT and anticipated greater patients getting access to treatment across the world. Some key players such as Exelixis (Cabozantinib), Daiichi Sankyo (DS-9606), and HiFiBiO Therapeutics (HFB200301) are investigating their candidates to treat GCT in the 7MM.
LAS VEGAS, Dec. 18, 2024 /PRNewswire/ -- DelveInsight's Germ Cell Tumors Market Insights report includes a comprehensive understanding of current treatment practices, germ cell tumors emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Germ Cell Tumors Market Report
- According to DelveInsight's analysis, the market size for germ cell tumors in the 7MM is expected to reach ~USD 630 million by 2034.
- Cabozantinib is expected to garner the largest market share of USD 129 million in the US by 2034, followed closely by DS-9606a, with a market share of USD 63 million.
- The incidence of GCT is around 26,000 cases in the 7MM in 2023.
- Leading germ cell tumors companies such as AstraZeneca, Exelixis, Pfizer, Xencor, Inc., Daiichi Sankyo, HiFiBiO Therapeutics, and others are developing novel germ cell tumors drugs that can be available in the germ cell tumors market in the coming years.
- The promising germ cell tumor therapies in the pipeline include Cabozantinib, Talazoparib, XmAb541, DS-9606a, and HFB200301, among others.
Discover which therapies are expected to grab the major Germ Cell Tumors market share @ Germ Cell Tumors Market Report
Germ Cell Tumors Overview
Germ cell tumors are a rare type of growth that originates from germ cells, the cells responsible for developing into sperm in males and eggs in females. These tumors can be benign or malignant and often develop in the gonads, but they can also arise in other areas of the body, such as the abdomen, chest, or brain.
The exact cause of germ cell tumors is not always clear, but genetic and environmental factors may play a role. Some known risk factors include abnormal development of the gonads, family history of similar conditions, and certain inherited syndromes.
Germ cell tumor symptoms depend on the tumor's location and size. Common signs include swelling or a mass in the affected area, abdominal or chest pain, difficulty breathing (in cases of tumors in the chest), or hormonal changes. In some cases, the tumors may cause symptoms such as fatigue or unexplained weight loss.
Germ cell tumor diagnosis typically involves a combination of imaging studies, blood tests to measure tumor markers like alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (β-hCG), and biopsy or surgical removal of the tumor to determine its nature. Early detection and treatment are crucial for improving outcomes, with therapies including surgery, chemotherapy, radiation, or a combination of these approaches.
Germ Cell Tumors Epidemiology Segmentation
The germ cell tumors epidemiology section provides insights into the historical and current germ cell tumors patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The germ cell tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Incident Cases of GCT
- Type-specific Incident Cases of GCT
- Sub-type specific Cases of Gonadal GCT
- Age-specific Cases of GCT
- Gender-specific Incident Cases of GCTs
- Total Incident Cases of GCTs by Stage
- Total Treatable Cases of GCT
- Line-wise Treatable Cases of GCT
Germ Cell Tumors Treatment Market
The treatment approach for germ cell tumors depends on the tumor type, whether ovarian or testicular. Surgery, followed by chemotherapy and sometimes radiation therapy, forms the cornerstone of GCT management. For recurrent testicular cancer, a chemotherapy combination of ifosfamide (Ifex), paclitaxel (Taxol), and cisplatin (Platinol) has proven highly effective. Notably, testicular cancers were among the first cancers successfully treated with radiation or chemotherapy.
Over 80% of patients with metastatic germ cell tumors achieve a cure with cisplatin-based chemotherapy, typically the bleomycin, etoposide, and cisplatin (BEP) regimen, combined with surgery for residual disease. However, only about 25% of patients who relapse attain long-term survival after second-line cisplatin-based therapy, often using the vinblastine, ifosfamide, and cisplatin (VeIP) regimen.
BEP remains the standard first-line chemotherapy for GCTs, effective in both seminomas and nonseminomas. This regimen capitalizes on cisplatin's DNA-damaging properties, etoposide's inhibition of DNA synthesis, and bleomycin's ability to induce DNA strand breaks, resulting in high cure rates. Treatment typically involves 3 to 4 cycles, tailored to disease stage and risk factors.
Advancements in surgical techniques, rising incidence rates, and improved post-surgical outcomes have increased the demand for surgical interventions, driving growth in the broader GCT treatment market.
To know more about germ cell tumor treatment guidelines, visit @ Germ Cell Tumors Management
Germ Cell Tumors Pipeline Therapies and Key Companies
- Durvalumab + Tremelimumab: AstraZeneca
- Cabozantinib: Exelixis
- Talazoparib: Pfizer
- XmAb541: Xencor, Inc.
- DS-9606a: Daiichi Sankyo
- HFB200301: HiFiBiO Therapeutics
Discover more about germ cell tumor drugs in development @ Germ Cell Tumors Clinical Trials
Germ Cell Tumors Market Dynamics
The germ cell tumors market dynamics are expected to change in the coming years. Platinum-based chemotherapy, such as the BEP regimen, is highly effective in treating both early and advanced-stage germ cell tumors, while surgical interventions like orchiectomy or oophorectomy also contribute significantly to successful outcomes. Biomarkers such as AFP, hCG, and LDH play a crucial role in diagnosis, staging, and monitoring treatment response, facilitating enhanced clinical decision-making and personalized care.
Ongoing research into the genetic and molecular drivers of GCTs holds promise for developing highly effective, less toxic therapies, particularly for refractory or relapsed cases. Furthermore, identifying and validating new biomarkers could improve diagnosis, risk stratification, and relapse detection, advancing personalized treatment approaches for patients, including those with non-secretory tumors.
Furthermore, potential therapies are being investigated for the treatment of germ cell tumors, and it is safe to predict that the treatment space will significantly impact the germ cell tumors market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the germ cell tumors market in the 7MM.
However several factors may impede the growth of the germ cell tumors market. Platinum-based chemotherapy is highly effective but is associated with significant acute toxicities, such as nephrotoxicity and ototoxicity, as well as long-term effects like secondary malignancies, which can severely impact the quality of life, particularly for young survivors. Additionally, approximately 10–15% of patients develop resistance to first-line therapies, leaving them with few effective options, as salvage treatments are often toxic and have limited success rates.
The emergence of resistance to platinum-based chemotherapy, especially in advanced or metastatic cases, poses a significant challenge, threatening the high cure rates associated with GCTs. Furthermore, the cost of advanced therapies, including novel drugs and long-term survivorship care, places a substantial financial burden on patients and healthcare systems, potentially limiting access to effective treatments.
Moreover, germ cell tumor treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, germ cell tumors market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact germ cell tumors market growth.
Germ Cell Tumors Market Report Metrics | Details |
Study Period | 2020–2034 |
Coverage | 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
Germ Cell Tumors Market CAGR | 5.5 % |
Germ Cell Tumors Market Size by 2034 | ~USD 630 Million |
Key Germ Cell Tumors Companies | AstraZeneca, Exelixis, Pfizer, Xencor, Inc., Daiichi Sankyo, HiFiBiO Therapeutics, and others |
Key Pipeline Germ Cell Tumors Therapies | Durvalumab + Tremelimumab, Cabozantinib, Talazoparib, XmAb541, DS-9606a, HFB200301, and others |
Scope of the Germ Cell Tumors Market Report
- Therapeutic Assessment: Germ Cell Tumors current marketed and emerging therapies
- Germ Cell Tumors Market Dynamics: Key Market Forecast Assumptions of Emerging Germ Cell Tumors Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Germ Cell Tumors Market Access and Reimbursement
Download the report to understand which factors are driving germ cell tumors market trends @ Germ Cell Tumors Market Trends
Table of Contents
1 | Key Insights |
2 | Report Introduction |
3 | Germ Cell Tumors (GCTs) Market Overview at a Glance |
3.1 | Market Share (%) Distribution of GCT by Therapies in 2023 |
3.2 | Market Share (%) Distribution of GCT by Therapies in 2034 |
4 | Methodology |
5 | Executive Summary |
6 | Key Events |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Types of GCT |
7.2.1 | Gonadal GCT |
7.2.2 | Extragonadal GCT |
7.3 | Germ Cell Tumors: From a Developmental Perspective |
7.4 | Molecular Features of GCT Precursors |
7.4.1 | Genomics of TGCTs |
7.4.2 | Genomic Landscape of PMGCTs |
7.5 | Sign and Symptoms |
7.6 | Diagnosis |
7.7 | Treatment Management |
8 | Epidemiology and Patient Population |
8.1 | Key Findings |
8.2 | Assumptions and Rationale |
8.3 | Total Incident Cases of GCT in the 7MM |
8.4 | Total Treatable Patient Pool of GCT in the 7MM |
8.5 | Total Treatable Cases of GCT by Line of Therapy in the 7MM |
8.6 | The United States |
8.6.1 | Total Incidence Cases of GCT in the United States |
8.6.2 | Type-specific Incidence Cases of GCT in the United States |
8.6.3 | Age-specific Cases of GCT in the United States |
8.6.4 | Sub-type specific Cases of Gonadal GCT in the United States |
8.6.5 | Gender-specific Incidence Cases of GCTs in the United States |
8.6.6 | Total Incident Cases of GCTs by Stage in the United States |
8.6.7 | Total Treatable Cases of GCT in the United States |
8.6.8 | Total Treatable Cases of GCT by Line of Therapy in the Unites States |
8.7 | EU4 and the UK |
8.7.1 | Total Incidence Cases of GCT in EU4 and the UK |
8.7.2 | Type specific Incidence Cases of GCT in EU4 and the UK |
8.7.3 | Age-specific Cases of GCT in EU4 and the UK |
8.7.4 | Sub-type specific Cases of Gonadal GCT in the United States |
8.7.5 | Gender-specific Incidence Cases of GCTs in EU4 and the UK |
8.7.6 | Total Incident Cases of GCTs by Stage in EU4 and the UK |
8.7.7 | Total Treatable Cases of GCT in EU4 and the UK |
8.7.8 | Total Treatable Cases of GCT by Line of Therapy in EU4 and the UK |
8.8 | Japan |
8.8.1 | Total Incidence Cases of GCT in Japan |
8.8.2 | Type specific Incidence Cases of GCT in Japan |
8.8.3 | Age-specific Cases of GCT in Japan |
8.8.4 | Sub-type specific Cases of Gonadal GCT in Japan |
8.8.5 | Gender-specific Incidence Cases of GCTs in Japan |
8.8.6 | Total Incident Cases of GCTs by Stage in Japan |
8.8.7 | Total Treatable Cases of GCT in Japan |
8.8.8 | Total Treatable Cases of GCT by Line of Therapy in Japan |
9 | Patient Journey |
10 | Emerging Therapies |
10.1 | Key Cross Competition |
10.2 | Durvalumab + Tremelimumab: AstraZeneca |
10.2.1 | Product Description |
10.2.2 | Clinical Development |
10.2.3 | Safety and efficacy |
10.3 | Cabozantinib: Exelixis |
10.3.1 | Product Description |
10.3.2 | Clinical Development |
10.3.3 | Safety and efficacy |
10.4 | Talazoparib: Pfizer |
10.4.1 | Product Description |
10.4.2 | Clinical Development |
10.5 | XmAb541: Xencor, Inc. |
10.5.1 | Product Description |
10.5.2 | Other Developmental Activities |
10.5.3 | Clinical Development |
10.6 | DS-9606a: Daiichi Sankyo |
10.6.1 | Product Description |
10.6.2 | Clinical Development |
10.6.3 | Safety and Efficacy |
10.7 | HFB200301: HiFiBiO Therapeutics |
10.7.1 | Product Description |
10.7.2 | Clinical Development |
10.7.3 | Safety and efficacy |
11 | Market Analysis |
11.1 | Key Findings |
11.2 | Market Outlook |
11.3 | Conjoint Analysis |
11.4 | Cost Assumptions |
11.5 | Key Market Forecast Assumptions |
11.6 | The 7MM Market Size |
11.6.1 | Total Market Size of GCT in the 7MM |
11.6.2 | Total Market Size of GCT by therapies in the 7MM |
11.7 | The United States |
11.7.1 | Total Market Size of GCT in the United States |
11.7.2 | Total Market size of GCT by Therapies in the United States |
11.8 | EU4 and the UK |
11.8.1 | Total Market Size of GCT in EU4 and the UK |
11.8.2 | Total Market Size of GCT by Therapies in EU4 and the UK |
11.9 | Japan |
11.9.1 | Total Market Size of GCT in Japan |
11.9.2 | Total Market Size of GCT by Therapies in Japan |
12 | KOL Views |
13 | SWOT Analysis |
14 | Unmet Needs |
15 | Market Access and Reimbursement |
15.1 | United States |
15.1.1 | Centre for Medicare and Medicaid Services (CMS) |
15.2 | EU4 and the UK |
15.2.1 | Germany |
15.2.2 | France |
15.2.3 | Italy |
15.2.4 | Spain |
15.2.5 | United Kingdom |
15.3 | Japan |
15.3.1 | MHLW |
16 | Appendix |
16.1 | Bibliography |
16.2 | Report Methodology |
17 | DelveInsight Capabilities |
18 | Disclaimer |
Related Reports
Non-small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others.
Non-small Cell Lung Cancer Pipeline
Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NSCLC companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others.
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.
Small-cell Lung Cancer Pipeline
Small-cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
Share this article